The broker said premium reductions for some life sciences clients came in at more than 40% during Q3, driven by increased market capacity and appetite, a trend expected to continue in Q1 2023.
Gallagher
The broker said premium reductions for some life sciences clients came in at more than 40% during Q3, driven by increased market capacity and appetite, a trend expected to continue in Q1 2023.
Gallagher